Tags

Type your tag names separated by a space and hit enter

High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
Bone Marrow Transplant. 2009 Mar; 43(6):481-9.BM

Abstract

We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26-68 years). High-dose melphalan (200 mg/m(2)) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded: complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, P<0.01. Response rates to ASCT were significantly low for patients with Hb <or=8.5 g/dl, serum albumin <or=3.3 g/dl, beta-2 microglobulin >5.5 mg/l, International Staging System stage III at diagnosis and >12 months interval from diagnosis to transplant. Grade III-IV mucositis was the major regimen-related toxicity. At a median follow-up of 70 months, the median overall survival and event free survival (EFS) were 71 and 42 months, respectively. Estimated overall survival and EFS at 60 months were 54.4+/-0.05% (s.e.) and 49.3+/-0.05% (s.e.), respectively. Survival was significantly better for patients with pre-transplant chemo-sensitive disease and for those who achieved complete response following transplant.

Authors+Show Affiliations

Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. lalitaiims@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18978818

Citation

Kumar, L, et al. "High-dose Chemotherapy With Autologous Stem Cell Transplantation for Multiple Myeloma: what Predicts the Outcome? Experience From a Developing Country." Bone Marrow Transplantation, vol. 43, no. 6, 2009, pp. 481-9.
Kumar L, Ghosh J, Ganessan P, et al. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant. 2009;43(6):481-9.
Kumar, L., Ghosh, J., Ganessan, P., Gupta, A., Hariprasad, R., & Kochupillai, V. (2009). High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplantation, 43(6), 481-9. https://doi.org/10.1038/bmt.2008.343
Kumar L, et al. High-dose Chemotherapy With Autologous Stem Cell Transplantation for Multiple Myeloma: what Predicts the Outcome? Experience From a Developing Country. Bone Marrow Transplant. 2009;43(6):481-9. PubMed PMID: 18978818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. AU - Kumar,L, AU - Ghosh,J, AU - Ganessan,P, AU - Gupta,A, AU - Hariprasad,R, AU - Kochupillai,V, Y1 - 2008/11/03/ PY - 2008/11/4/pubmed PY - 2009/8/14/medline PY - 2008/11/4/entrez SP - 481 EP - 9 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 43 IS - 6 N2 - We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26-68 years). High-dose melphalan (200 mg/m(2)) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded: complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, P<0.01. Response rates to ASCT were significantly low for patients with Hb <or=8.5 g/dl, serum albumin <or=3.3 g/dl, beta-2 microglobulin >5.5 mg/l, International Staging System stage III at diagnosis and >12 months interval from diagnosis to transplant. Grade III-IV mucositis was the major regimen-related toxicity. At a median follow-up of 70 months, the median overall survival and event free survival (EFS) were 71 and 42 months, respectively. Estimated overall survival and EFS at 60 months were 54.4+/-0.05% (s.e.) and 49.3+/-0.05% (s.e.), respectively. Survival was significantly better for patients with pre-transplant chemo-sensitive disease and for those who achieved complete response following transplant. SN - 1476-5365 UR - https://www.unboundmedicine.com/medline/citation/18978818/High_dose_chemotherapy_with_autologous_stem_cell_transplantation_for_multiple_myeloma:_what_predicts_the_outcome_Experience_from_a_developing_country_ L2 - https://doi.org/10.1038/bmt.2008.343 DB - PRIME DP - Unbound Medicine ER -